Tasly Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has an Asset Resilience Ratio of 14.98% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600535 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Tasly Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Tasly Pharmaceutical Group Co Ltd balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Tasly Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 600535 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.29 Billion | 14.98% |
| Total Liquid Assets | CN¥2.29 Billion | 14.98% |
Asset Resilience Insights
- Moderate Liquidity: Tasly Pharmaceutical Group Co Ltd has 14.98% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Tasly Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tasly Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Tasly Pharmaceutical Group Co Ltd (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Tasly Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.09% | CN¥1.39 Billion ≈ $204.00 Million |
CN¥15.34 Billion ≈ $2.24 Billion |
+5.58pp |
| 2024-12-31 | 3.50% | CN¥524.72 Million ≈ $76.78 Million |
CN¥14.98 Billion ≈ $2.19 Billion |
+1.70pp |
| 2023-12-31 | 1.80% | CN¥300.71 Million ≈ $44.00 Million |
CN¥16.71 Billion ≈ $2.45 Billion |
-5.05pp |
| 2022-12-31 | 6.85% | CN¥1.12 Billion ≈ $164.62 Million |
CN¥16.43 Billion ≈ $2.40 Billion |
-2.15pp |
| 2021-12-31 | 8.99% | CN¥1.49 Billion ≈ $217.66 Million |
CN¥16.54 Billion ≈ $2.42 Billion |
+8.13pp |
| 2020-12-31 | 0.87% | CN¥142.92 Million ≈ $20.91 Million |
CN¥16.49 Billion ≈ $2.41 Billion |
+0.62pp |
| 2019-12-31 | 0.25% | CN¥59.39 Million ≈ $8.69 Million |
CN¥24.01 Billion ≈ $3.51 Billion |
-0.38pp |
| 2018-12-31 | 0.63% | CN¥158.30 Million ≈ $23.16 Million |
CN¥25.17 Billion ≈ $3.68 Billion |
-1.94pp |
| 2017-12-31 | 2.57% | CN¥552.66 Million ≈ $80.87 Million |
CN¥21.53 Billion ≈ $3.15 Billion |
+1.00pp |
| 2016-12-31 | 1.56% | CN¥267.90 Million ≈ $39.20 Million |
CN¥17.13 Billion ≈ $2.51 Billion |
-0.19pp |
| 2015-12-31 | 1.76% | CN¥270.50 Million ≈ $39.58 Million |
CN¥15.41 Billion ≈ $2.26 Billion |
+1.39pp |
| 2014-12-31 | 0.36% | CN¥46.85 Million ≈ $6.86 Million |
CN¥12.92 Billion ≈ $1.89 Billion |
-0.47pp |
| 2013-12-31 | 0.83% | CN¥84.96 Million ≈ $12.43 Million |
CN¥10.21 Billion ≈ $1.49 Billion |
+0.58pp |
| 2012-12-31 | 0.25% | CN¥19.00 Million ≈ $2.78 Million |
CN¥7.49 Billion ≈ $1.10 Billion |
-0.36pp |
| 2006-12-31 | 0.61% | CN¥20.04 Million ≈ $2.93 Million |
CN¥3.26 Billion ≈ $477.01 Million |
-2.66pp |
| 2005-12-31 | 3.27% | CN¥90.08 Million ≈ $13.18 Million |
CN¥2.75 Billion ≈ $403.06 Million |
+2.82pp |
| 2004-12-31 | 0.46% | CN¥10.02 Million ≈ $1.47 Million |
CN¥2.20 Billion ≈ $322.08 Million |
-- |
About Tasly Pharmaceutical Group Co Ltd
Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical… Read more